Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment

Stroke

Volumn 35, Issue 4, 2004, Pages 1010-1017

  Erkinjuntti, Timo ^a   Román, Gustavo ^b   Gauthier, Serge ^c   Feldman, Howard ^d   Rockwood, Kenneth ^e  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Carbamates; Cognitive disorders; Dementia; Donepezil; Galantamine; Memantine; Nimodipine; Piperidines; Rivastigmine; Vascular diseases

Indexed keywords

ACETYLCHOLINE; ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; ANTIOXIDANT; CALCIUM ANTAGONIST; CHOLINESTERASE INHIBITOR; DONEPEZIL; ERGOT ALKALOID; GALANTAMINE; GINKGO BILOBA EXTRACT; GLUTAMIC ACID; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIMODIPINE; NOOTROPIC AGENT; OXYGEN; PROPENTOFYLLINE; PROTIRELIN DERIVATIVE; RIVASTIGMINE; SEROTONIN ANTAGONIST; VASOACTIVE AGENT; XANTHINE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; BRAIN INFARCTION; CADASIL; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DAILY LIFE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; STROKE;

CARBAMATES; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISORDERS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; CONTROLLED CLINICAL TRIALS; DEMENTIA, VASCULAR; GALANTAMINE; HUMANS; INDANS; PHENYLCARBAMATES; PIPERIDINES; RISK FACTORS; TERMINOLOGY;

EID: 1842418653     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000120731.88236.33     Document Type: Article

References (87)

1. Launer LJ, Hofman A. Frequency and impact of neurologic diseases in the elderly of Europe: a collaborative study of population-based cohorts. Neurology. 2000;54(suppl 5):S1-S3.
2. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA. 1997;277:813-817.
3. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet. 1999;354:919-920.
4. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study: pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet. 2001;357:169-175.
5. Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M. Comparison of stroke features and disability in daily life in patients with ischemic stroke aged 55 to 70 and 71 to 85 years. Stroke. 1997;28:729-735.
6. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Kloudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003;34:1126-1129.
7. Rockwood K, Howard K, MacKnight C, Darvesh S. Spectrum of disease in vascular cognitive impairment. Neuroepidemiology. 1999;18:248-254.
8. Wentzel C, Rockwood K, MacKnight C. Progression of impairment in patients with vascular cognitive impairment without dementia. Neurology. 2001;57:714-716.
9. Rockwood K, Davis H, MacKnight C, Vandorpe R, Gauthier S, Guzman A, et al. The consortium to investigate vascular impairment of cognition: methods and first findings. Can J Neurol Sci. 2003;30:237-243.
10. Román GC. Stroke, cognitive decline and vascular dementia: the silent epidemic of the 21st century. Neuroepidemiology. 2003;22:161-164.
11. Erkinjuntti T, Hachinski VC. Rethinking vascular dementia. Cerebrovasc Dis. 1993;3:3-23.
12. Erkinjuntti T. Cerebrovascular dementia: pathophysiology, diagnosis and treatment. CNS Drugs. 1999;12:35-48.
13. Hachinski VC, Iliff LD, Zilhka E, Du BG, McAllister VL, Marshall J, Russell RW, Symon L. Cerebral blood flow in dementia. Arch Neurol. 1975;32:632-637.
14. Román GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol. 2002;1:426-436.
15. Bowler JV, Steenhuis R, Hachinski V. Conceptual background of vascular cognitive impairment. Alzheimer Dis Assoc Disord. 1999;13: S30-S37.
16. Rockwood K, Wenzel C, Hachinski V. Prevalence and outcomes of vascular cognitive impairment. Neurology. 2000;54:447-451.
17. O'Brien JT, Erkinjuntti T, Reisberg B, Román G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST. Vascular cognitive impairment. Lancet Neurol. 2003;2:89-98.
18. Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tinklenberg J, Chang FL, Skinner K, Tasaki C, Jagust WJ. Clinical criteria for the diagnosis of vascular dementia. Arch Neurol. 2000:57:191-196.
19. Pohjasvaara T, Mäntylä R, Ylikoski R, Aronen HJ, Kaste M, Erkinjuntii T. Comparison of different clinical criteria for the vascular cause of vascular dementia (ADDTC, DSM-III, DSM-IV, ICD-10, NINDS-AIREN). Stroke 2000;31:2952-2957.
20. Gold G, Bouras C, Canuto A, Bergallo MF, Herrmann FR, Hof PR, Mayor PA, Michel JP, Giannakopoulos P. Clinicopathological validation criteria for vascular dementia. Am J Psychiatry 2002;159:82-87.
21. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology. 1992;42:473-480.
22. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Work Group. Neurology. 1993;43:250-260.
23. Erkinjuntti T, Rockwood K. Vascular cognitive impairment. Psychogeriatrics. 2001;1:27-38.
24. Ballard C, McKeith I, O'Brien J, Kalaria R, Jaros E, Ince P, Perry R. Neuropathological substrates of dementia and depression in vascular dementia, with a particular focus on cases with small infarct volumes. Dement Geriatr Cogn Disord. 2000;11:59-65.
25. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797-811.
26. Desmond DW, Erkinjuntti T, Sano M, Cummings JL, Bowler JV, Pasquier F, Moroney JT, Ferris SH, Stern Y, Sachdev PS, Hachinski V. The cognitive syndrome of vascular dementia: implications for clinical trials. Alzheimer Dis Assoc Disord. 1999;(suppl 3):S21-S29.
27. Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, Román GC, Chui H, Desmond DW. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm. 2000; 59(suppl 1):23-30.
28. Román GC, Royall DR. Executive control function: a rational basis for the diagnosis of vascular dementia. Alzheimer Dis Assoc Disord. 1999; 13(suppl 3):69-80.
29. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(suppl 3):S115-S123.
30. Zekry, D, Hauw JJ, Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc. 2002;50:1431-1438.
31. Zekry D, Duyckaerts C, Belmin J, Geoffre C, Moulias R, Hauw JJ. Alzheimer's disease and brain infarcts in the elderly: agreement with neuropathology. J Neurol. 2002;249:1529-1534.
32. Royall DR, Palmer R, Mulroy A, Polk MJ, Román GC, David J-P, Delacourte A. Pathological determinants of clinical dementia in Alzheimer's disease. Exp Aging Res. 2002;28:143-162.
33. Chui HC, Gonthier R. Natural history of vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(suppl 3):S124-S130.
34. Wolfson C, Wolfson DB, Asgharian M, M'Lan CE, Ostbye T, Rockwood K, Hogan DB, Clinical Progression of Dementia Study Group. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344:1111-1116.
35. Kitnner B, Rossner M, Rother M. Clinical trials in dementia with propentofylline. Ann N Y Acad Sci. 1997;826:307-316.
36. Skoog I, Risk factors for vascular dementia: a review. Dementia. 1994 5:137-144.
37. Smith AD. Homocysteine, B vitamins, and cognitive deficit in the elderly. Am J Clin Nutr. 2002;75:785-786.
38. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046-2052.
39. Gorelick PB. Neuroprotection in acute ischaemic stroke: a tale of for whom the bell tolls? Lancet. 2000;355:1925-1926.
40. Klijn CJ, Hankey GJ, American Stroke Association, European Stroke Initiative. Management of acute ischaemic stroke: new guidelines from the American Stroke Association and the European Stroke Initiative. Lancet Neurol. 2003;2:698-701.
41. Gorelick PB. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. Stroke. 2002;33:862-875.
42. Moroney JT, Bagiella E, Desmond DW, Paik MC, Stern Y, Tatemichi TK. Risk factors for incident dementia after stroke: role of hypoxic ischemic disorders. Stroke. 1996;27:1283-1289.
43. Callahan A. Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention. Am J Cardiol. 2001;88:J33-J37.
44. Rockwood K, Darvesh S. The risk of dementia in relation to statins and other lipid lowering agents. Neurol Res. 2003;25:601-604.
45. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann I. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98:5856-5861.
46. Darvesh S, Martin E, Walsh R, Rockwood K. Differential effects of lipid-lowering agents on human cholinesterases. Clin Biochem. 2004;37: 42-49.
47. The PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003; 163:1069-1075.
48. Rockwood K, Gauthier S, Erkinjuntti T. Prevention and treatment of vascular dementia. In: Erkinjuntti T, Gauthier S, eds. Vascular Cognitive Impairment. London, UK: Martin Duniz Ltd; 2002:587-595.
49. Sawada T, Whitehouse PJ. Regulatory guidelines for antidementia drugs. In: Erkinjuntti T, Gauthier S, eds. Vascular Cognitive Impairment. London, UK: Martin Duniz Ltd: 2002:619-627.
50. Ferris S, Gauthier S. Cognitive outcome measures in vascular dementia. In: Erkinjuntii T, Gauthier S, eds. Vascular Cognitive Impairment. London, UK: Martin Duniz Ltd; 2002:395-400.
51. Quinn J, Moore M, Benson DF, Clark CM, Doody R, Jagust W, Knopman D, Kaye JA. A videotaped CIBIC for dementia patients: validity and reliability in a simulated clinical trial. Neurology. 2002;58:433-437.
52. Orgogozo J-M, Rigaud A-S, Stöffler A, Möbius H-J, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33:1834-1839.
53. Royall DR. Executive cognitive impairment: a novel perspective on dementia. Neuroepidemiology. 2000;19:293-299.
54. Pohjasvaara T, Leskelä M, Vataja R. Kalska H. Ylikoski R, Hietanen M, Leppavuori A. Kaste M. Erkinjuntti T. Post-stroke depression executive dysfunction and functional outcome. Eur J Neurol. 2002;9:269-275.
55. Chui E, Yastrubetskaya O, Williams M. Pharmacotherapy of mood and behavior symptoms In: Erkinjuntti T. Gauthier S, eds. Vascular Cognitive Impairment. London, UK: Martin Duniz Ltd; 2002:597-605.
56. Gauthier S. Gélinas I. Evaluation of daily activities in vascular cognitive impairment. In: Erkinjuntti T. Gauthier S, eds. Vascular Cognitive Impairment. London. UK: Martin Duniz Ltd; 2002:411-416.
57. Walsh AC, Walsh BH. Melaney C. Senile-presenile dementia: follow-up data on an effective psychotherapy-anticoagulant regimen. J Am Geriatr. Soc. 1978;26:467-470.
58. Román GC. Perspectives in the treatment of vascular dementia. Drugs Today. 2000;36:641-653.
59. Mielke R, Möller H-J, Erkinjunti T, Rosenkranz B, Rother M, Kittner B. Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials. Alzheimer Dis Assoc Disord. 1998;12(suppl 2):29-35.
60. Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D. A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol. 1996;19:497-506.
61. Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, Wallin A: Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci. 2000;175:124-134.
62. Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjunti T. The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci. 2000;175:116-123.
63. Lopez-Arieta BJ. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2001;1:CD000147.
64. Görtelmeyer R, Erbler H. Memantine in treatment of mild to moderate dementia syndrome. Drug Res. 1992;42:904-912.
65. Wilcock G, Möbius HJ, Stöffler A, on behalf of the MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Internat Clin Psychopharmacol. 2002;17:297-305.
66. Möbius HI. Stöffler A. New approaches to clinical trials in vascular dementia: memantine in small vessel disease. Cerebrovasc Dis. 2002; 13(suppl 2):62-66.
67. Gottfries CG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia. 1994;5:163-167.
68. Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagust WJ; Mack WJ, Chui HC. Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol. 2000;60:658-659.
69. Selden NR, Gitelman DR, Salamon-Murayama N, Parrsh TB, Mesulam MM. Trajectories of cholinergic pathways within the cerebral hemispheres of the human brain. Brain. 1998;121:2249-2257.
70. Swartz RH, Sahlas DJ, Black SE. Strategic involvement of cholinetgic pathways and executive dysfunction: does location of white matter signal hyperintensities matter? J Stroke Cerebrovasc Dis. 2003;12:29-36.
71. Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology. 2003;60: 1183-1185.
72. Togashi H, Matsumoto K. Yoshida M. Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rat. Neurosci Lett. 1994;166:117-120.
73. Court JA, Perry EK, Kalaria RN. Neurotransmitter control of cerebral vasculature an abnormalities in vascular dementia. In: Erkinjuntti T, Gauthier S, eds. Vascular Cognitive Impairment. London, UK: Martin Duniz, Ltd; 2002:167-185.
74. Román GC, Rogers SJ. Donepezil: a clinical review of current and emerging: indications. Expert Opin Pharmacother. 2004;5:161-180.
75. Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A, Perdomo C, Kumar D, Pratt R, Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323-2332.
76. Wilkinson D, Doody R, Helme R, Taubman K, Minzer J, Kertesz A, Pratt R, Donepezil 308 Study Group. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003;61:479-486.
77. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283-1290.
78. Gélinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia. Am J Occup Ther. 1999;53:471-481.
79. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.
80. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther. 2003;25:1765-1782.
81. Rockwood K, MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology. 2001;20:51-56.
82. Cohen J. Statistical Power Calculations for the Behavioural Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
83. Rockwood K. Clinical meaningfulness in relation to the size of the treatment effect of cholinesterase inhibition on cognition in Alzheimer's disease. Neurobiol Aging. 2002;23:S168, 628.
84. Livingston G, Katona C. How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatr Psychiatry. 2000;15:203-207.
85. Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol. 2001;8:361-362.
86. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci. 2002;203:141-146.
87. Erkinjuntti T, Skoog I, Lane R, Andrews C. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. Int J Clin Pract. 2002; 56:791-796.